How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-cyclophosphamide-paclitaxel-dabepoetin-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa (Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with erythropoiesis-stimulating agent. Area: Oncology.

phase 3 Chemotherapy combination with erythropoiesis-stimulating agent DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa (Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa) — GBG Forschungs GmbH. This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa TARGET	Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa	GBG Forschungs GmbH	phase 3	Chemotherapy combination with erythropoiesis-stimulating agent	DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with erythropoiesis-stimulating agent class)

GBG Forschungs GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-cyclophosphamide-paclitaxel-dabepoetin-alfa. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab